


Product Name : PF-07817883
Cat. No. : PC-22258
CAS No. : 2755812-39-4
Molecular Formula : C₂₁H₃₀F₃N₅O₅
Molecular Weight : 489.50
Target : SARS-CoV-2 Inhibitors
Solubility : 10 mM in DMSO



Biological Activity

PF-07817883 (Ibuzatrelvir) is a second-generation, orally bioavailable, SARS-CoV-2 main protease (**Mpro**) with K_i value of 2.48 nM, EC₅₀ of 180 nM for inhibition of SARS-CoV-2 induced cytopathic effect (CPE).

PF-07817883 (Ibuzatrelvir) shows improved metabolic stability versus nirmatrelvir, the antiviral component of the ritonavir-boosted therapy Paxlovid.

PF-07817883 (Ibuzatrelvir) inhibits the SARS-CoV-1 Mpro (IC₅₀ = 18 nM) and MERS Mpro (IC₅₀ = 930 nM) activity, respectively, but has a much smaller disparity in the cell-based antiviral assays (SARS-CoV-1 EC₅₀ = 157 nM and MERS EC₅₀ = 158 nM).

PF-07817883 (Ibuzatrelvir) potently inhibits SARS-CoV-2 viral replication with EC₅₀ and EC₉₀ values of 34 nM and 70 nM respectively in Vero76 cells.

PF-07817883 (Ibuzatrelvir) also demonstrated oral efficacy in a mouse-adapted SARS-CoV-2 model at plasma concentrations equivalent to nirmatrelvir.

References

Allerton CMN, et al. *J Med Chem*. 2024 Apr 30. doi: 10.1021/acs.jmedchem.3c02469.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com